QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Mr. Thierry Bernard is the Chief Executive Officer of Qiagen NV, joining the firm since 2020.
What is the price performance of QGEN stock?
The current price of QGEN is $39.49, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Qiagen NV?
Qiagen NV belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is Qiagen NV market cap?
Qiagen NV's current market cap is $8.1B
Is Qiagen NV a buy, sell, or hold?
According to wall street analysts, 18 analysts have made analyst ratings for Qiagen NV, including 5 strong buy, 8 buy, 11 hold, 0 sell, and 5 strong sell